Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Jan 10, 2023 2:35pm
131 Views
Post# 35214014

RE:Something to think about...

RE:Something to think about...
EbbFlow88 wrote: Something I can't stop thinking about is that the current market cap is around $585M assuming 112.5M shares outstanding at the current price.

Biotoscana was purchased for $369M CAD and Exelon was purchased for $217M CAD. Neither of which was purchased at a high multiple. Total purchases of those two assets = $586M

Excluding the recent debt deal, substract cash + equivalents and financial assets from Mcap and you get ~290M CAD for GBT and drugs.

585 - 145 - 150 = 290M

So, at today's price, buyers are getting those assets at .50 on the dollar for what was paid, which our frugal management team deemed worth the purchase. 

Also, ~45M in cash from Ops is a return on that 290M of 15.5%

Either they way overpaid for those assets (as chianchin most definitely believes) or this is an unbelievable gift from the market. My money is on the latter. 


If you believe that tthe tax assessment will go our way. You can add  46M to our cash total. Making the market value of the base operations  ~$250M which yields 18% cash.

Separately, there has been no filings for stock buybacks last month. Usually, at this point in the following month that has been filed. Maybe it's late or maybe we stopped buying back shares. 

No question that volume has dried up in January. So, if we're done buying at the moment along with new $50M CAD in debt, maybe we're closer to M&A deal. 
<< Previous
Bullboard Posts
Next >>